Literature DB >> 33217029

Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis.

Jonathon P Schubert1,2, Jessica Gehlert2, Christopher K Rayner1,3, Ian C Roberts-Thomson1, Sam Costello1,4, Arduino A Mangoni2, Robert V Bryant1,4.   

Abstract

OBJECTIVE: While the global prevalence of antibiotic-resistant Helicobacter pylori (H. pylori) is increasing, there is much regional variation, and local data are required to guide eradication therapy. We performed a systematic review and meta-analysis to determine rates of H. pylori antibiotic resistance in Australia and New Zealand. STUDY
DESIGN: Random effects meta-analysis of data from 15 published studies and three published abstracts reporting prevalence of primary or secondary H. pylori antibiotic resistance in Australasia. DATA SOURCES: PubMed, EMBASE, MEDLINE, PROSPERO, and the Cochrane Library were searched until August, 2020. DATA SYNTHESIS: Fifteen published studies and three published abstracts were identified; one study was excluded due to high risk of bias. Seventeen studies conducted between 1996 and 2013 were included in the final analysis, 12 reporting primary and five reporting secondary antibiotic resistance. Prevalence of primary resistance was clarithromycin 7.4% (95% confidence interval [CI], 5.3-9.7%), metronidazole 50.0% (95%CI, 23.9-56.1%), fluoroquinolones 3.7% (95%CI, 0.004-14.8%), and both amoxicillin and tetracycline <0.5%. Subgroup analysis (last 20 years) showed doubling of clarithromycin resistance to 16.1% (95%CI 11.2-21.7%) with other resistance stable. Prevalence of secondary resistance was high for all antibiotics, particularly clarithromycin 78.7% (95%CI, 64.1-90.1%) and metronidazole 68.3% (95%CI, 59.9-76.1%).
CONCLUSIONS: The outcomes reveal an increase in primary H. pylori clarithromycin resistance since the year 2000, while metronidazole resistance has remained stable and primary resistance to amoxicillin, tetracycline, and fluoroquinolones is low. Rates of secondary resistance to metronidazole and clarithromycin are high. The results highlight the need for contemporary local data on antibiotic resistance in Australia and New Zealand.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Australia; Helicobacter pylori; New Zealand; antibiotic; antimicrobial; resistance

Year:  2021        PMID: 33217029     DOI: 10.1111/jgh.15352

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Study on the value of antibiotic-resistant gene detection in Helicobacter pylori in China.

Authors:  Jinfeng Dai; Jing Zhao; Liqi Mao; Yue Hu; Bin Lv
Journal:  Exp Ther Med       Date:  2022-01-18       Impact factor: 2.447

2.  The Influence of Past Metronidazole Exposure on the Outcome of Helicobacter pylori Eradication.

Authors:  Younghee Choe; Joon Sung Kim; Hyun Ho Choi; Dae Bum Kim; Jae Myung Park; Jung Hwan Oh; Tae Ho Kim; Dae Young Cheung; Woo Chul Chung; Byung-Wook Kim; Sung Soo Kim
Journal:  Front Microbiol       Date:  2022-03-25       Impact factor: 5.640

3.  Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.

Authors:  Ruilin Wang; Yanling Wang; Zheng Lu; Jing Jing; Zhongxia Wang; Tingting He; Miao Tian; Zongyang Yuan; Yanfei Cui; Wenya Rong; Xiao Ma; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-07       Impact factor: 2.650

Review 4.  Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations.

Authors:  Roberto Grosso; M-Violante de-Paz
Journal:  Pharmaceutics       Date:  2022-06-24       Impact factor: 6.525

5.  Geospatial analysis of Helicobacter pylori infection in South Australia: Should location influence eradication therapy?

Authors:  Jonathon P Schubert; Richard J Woodman; Arduino A Mangoni; Christopher K Rayner; Morgyn S Warner; Ian C Roberts-Thomson; Samuel P Costello; Robert V Bryant
Journal:  J Gastroenterol Hepatol       Date:  2022-03-31       Impact factor: 4.369

6.  Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.

Authors:  Anoja W Gunaratne; Harrison Hamblin; Annabel Clancy; Aleja Jane Marie C Magat; Marie Vic M Dawson; Jeffrey Tu; Thomas J Borody
Journal:  Helicobacter       Date:  2021-07-10       Impact factor: 5.753

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.